Načítá se...
The PIKfyve Inhibitor Apilimod: A Double-Edged Sword against COVID-19
The PIKfyve inhibitor apilimod is currently undergoing clinical trials for treatment of COVID-19. However, although apilimod might prevent viral invasion by inhibiting host cell proteases, the same proteases are critical for antigen presentation leading to T cell activation and there is good evidenc...
Uloženo v:
| Vydáno v: | Cells |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
MDPI
2020
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7824419/ https://ncbi.nlm.nih.gov/pubmed/33375410 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cells10010030 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|